Statins and Inflammation
- PMID: 34851454
- DOI: 10.1007/s11883-021-00977-6
Statins and Inflammation
Abstract
Purpose of review: Chronic inflammation has been recognized as one of the most important pathophysiological mechanisms' initiation and progression of atherosclerosis. Statins belong to most successful therapeutic agents in the prevention and treatment of atherothrombotic vascular disease. Their non-lipid related effects including suppression of inflammation have been repeatedly proven in both experimental and clinical settings.
Recent findings: Recently, the importance of inflammation in the process of atherosclerosis has been confirmed by interventions targeting inflammation selectively. Clinical trial with selective inhibitor of a principal inflammatory mediator interleukin 1-beta - canakinumab - confirmed the notion of direct vasculoprotective effects of primarily targeting inflammation. This has increased interest in the non-lipid, pleiotropic and, particularly, anti-inflammatory effects of statins. Anti-inflammatory effects of statins have been proven both experimentally and in clinical settings beyond any doubt. They comprise a direct positive effect on not only many cell types and pathways that are lipid independent but, also, some that are mediated by lipid modification. Undoubtedly, suppression of inflammatory response by statins contributes to their generally positive action in atherosclerosis and represents an important part of the vasculo- and atheroprotective effect of this drug class.
Keywords: Atherosclerosis; Biomarkers; Cardiovascular; Endothelial function; Inflammation; Pleiotropy; Statins.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol.Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):441-53. doi: 10.2174/156800605774962077. Curr Drug Targets Cardiovasc Haematol Disord. 2005. PMID: 16503864 Review.
-
Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms.Int J Biochem Cell Biol. 2020 May;122:105735. doi: 10.1016/j.biocel.2020.105735. Epub 2020 Feb 29. Int J Biochem Cell Biol. 2020. PMID: 32126319 Review.
-
Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins.J Am Coll Cardiol. 2014 Jun 17;63(23):2491-2502. doi: 10.1016/j.jacc.2014.01.054. Epub 2014 Mar 5. J Am Coll Cardiol. 2014. PMID: 24613322 Review.
-
Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.Curr Med Chem. 2007;14(2):243-8. doi: 10.2174/092986707779313381. Curr Med Chem. 2007. PMID: 17266583 Review.
-
The interplay between statins and adipokines. Is this another explanation of statins' 'pleiotropic' effects?Cytokine. 2021 Dec;148:155698. doi: 10.1016/j.cyto.2021.155698. Epub 2021 Sep 16. Cytokine. 2021. PMID: 34537488 Review.
Cited by
-
The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis.Front Cardiovasc Med. 2022 Jul 27;9:936817. doi: 10.3389/fcvm.2022.936817. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35966518 Free PMC article.
-
Lipids, lipid-lowering drug target genes and pancreatic cancer: a Mendelian randomization study.Int J Clin Pharm. 2025 Jun;47(3):747-754. doi: 10.1007/s11096-025-01866-7. Epub 2025 Jan 17. Int J Clin Pharm. 2025. PMID: 39821006
-
Targeting gut microbiota and immune crosstalk: potential mechanisms of natural products in the treatment of atherosclerosis.Front Pharmacol. 2023 Sep 1;14:1252907. doi: 10.3389/fphar.2023.1252907. eCollection 2023. Front Pharmacol. 2023. PMID: 37719851 Free PMC article. Review.
-
Low Vitamin D Status Attenuates Hypolipidemic and Pleiotropic Effects of Atorvastatin in Women.Nutrients. 2025 May 15;17(10):1674. doi: 10.3390/nu17101674. Nutrients. 2025. PMID: 40431414 Free PMC article.
-
New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease.Biomedicines. 2022 Apr 22;10(5):970. doi: 10.3390/biomedicines10050970. Biomedicines. 2022. PMID: 35625707 Free PMC article. Review.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
-
- Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, 2004. 364(9438), 937–952. https://doi.org/10.1016/S0140-6736(04)17018-9 .
-
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020. 41(1) 111–188.
-
- •• Montecucco F, Liberale L, Bonaventura A, et al. The role of inflammation in cardiovascular outcome. Curr Atheroscler. 2017. Rep. 9(3)11. A comprehensive review focusing on and summarizing the roles of innate immunity in the vascular inflammation initiation and propagation and its role in cardiovascular events risk.
-
- Chatzizisis Y, CoskunA, Jonas M, et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49:2379–93.
-
- •• Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1696. A landmark paper summarizing the inflammatory aspects of atherosclerosis and involvement of different cellular and chemical species in different stages of atherogenesis.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials